The MDM2-p53 pathway revisited

The p53 tumor suppressor is a key transcription factor regulating cellular pathways such as DNA repair, cell cycle, apoptosis, angiogenesis, and senescence. It acts as an important defense mechanism against cancer onset and progression, and is negatively regulated by interaction with the oncoprotein MDM2. In human cancers, the TP53 gene is frequently mutated or deleted, or the wild-type p53 function is inhibited by high levels of MDM2, leading to downregulation of tumor suppressive p53 pathways. Thus, the inhibition of MDM2-p53 interaction presents an appealing therapeutic strategy for the treatment of cancer. However, recent studies have revealed the MDM2-p53 interaction to be more complex involving multiple levels of regulation by numerous cellular proteins and epigenetic mechanisms, making it imperative to reexamine this intricate interplay from a holistic viewpoint. This review aims to highlight the multifaceted network of molecules regulating the MDM2-p53 axis to better understand the pathway and exploit it for anticancer therapy.

[1]  Lei Xiong,et al.  A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop , 2007, The Journal of cell biology.

[2]  Do-Hyoung Kim,et al.  Structural Details on mdm2-p53 Interaction* , 2005, Journal of Biological Chemistry.

[3]  Chong Li,et al.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.

[4]  A. Haas,et al.  Hdm2 is an Ubiquitin Ligase of Ku70 -Akt Promotes Cell Survival by Inhibiting Hdm2-dependent Ku70 Destabilization , 2008, Cell Death and Differentiation.

[5]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[6]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[7]  Weiya Ma,et al.  Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability , 2013, Oncogene.

[8]  Hui Wang,et al.  Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models , 2004, Clinical Cancer Research.

[9]  Cédric Kalinski,et al.  Isoquinolin‐1‐one Inhibitors of the MDM2–p53 Interaction , 2008, ChemMedChem.

[10]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[11]  L. Weber,et al.  Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present) , 2013, Expert opinion on therapeutic patents.

[12]  K. Hemminki,et al.  MDM2 SNP309 and cancer risk: a combined analysis. , 2007, Carcinogenesis.

[13]  Qi Zhang,et al.  Ribosomal protein S14 unties the MDM2–p53 loop upon ribosomal stress , 2013, Oncogene.

[14]  J. Buolamwini,et al.  Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. , 2005, Current cancer drug targets.

[15]  A. Jochemsen,et al.  Mdmx and Mdm2: Brothers in Arms? , 2004, Cell cycle.

[16]  Hui Wang,et al.  Oncogenes as Novel Targets for Cancer Therapy (Part I) , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[17]  J. Little,et al.  ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation , 2000, Oncogene.

[18]  Xinjiang Wang.  p53 regulation: Teamwork between RING domains of Mdm2 and MdmX , 2011, Cell cycle.

[19]  Pengfei Li,et al.  MDM2 Acts Downstream of p53 as an E3 Ligase to Promote FOXO Ubiquitination and Degradation* , 2009, Journal of Biological Chemistry.

[20]  Mong-Hong Lee,et al.  14-3-3σ Positively Regulates p53 and Suppresses Tumor Growth , 2003, Molecular and Cellular Biology.

[21]  Hui Wang,et al.  Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. , 2005, Current cancer drug targets.

[22]  Toshiyuki Obata,et al.  Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53* , 2002, The Journal of Biological Chemistry.

[23]  Pier Paolo Pandolfi,et al.  The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation* , 2003, Journal of Biological Chemistry.

[24]  R. Tjian,et al.  Repression of p53-mediated transcription by MDM2: a dual mechanism. , 1997, Genes & development.

[25]  Hui Wang,et al.  Novel MDM2 p53‐Independent Functions Identified through RNA Silencing Technologies , 2005, Annals of the New York Academy of Sciences.

[26]  Mong-Hong Lee,et al.  Roles for CSN5 in control of p53/MDM2 activities , 2008, Journal of cellular biochemistry.

[27]  Xinjiang Wang,et al.  Mdm2 and MdmX partner to regulate p53 , 2012, FEBS letters.

[28]  F. McCormick,et al.  Opposing Effects of Ras on p53 Transcriptional Activation of mdm2 and Induction of p19ARF , 2000, Cell.

[29]  Hui Wang,et al.  MDM2 oncogene as a novel target for human cancer therapy. , 2000, Current pharmaceutical design.

[30]  U. Francke,et al.  Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line , 1987, Somatic cell and molecular genetics.

[31]  Hui Wang,et al.  RYBP stabilizes p53 by modulating MDM2 , 2009, EMBO reports.

[32]  O. Cuvier,et al.  Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2 , 2007, Nature Cell Biology.

[33]  U. Moll,et al.  The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.

[34]  R. Honda,et al.  Mammalian Numb is a target protein of Mdm2, ubiquitin ligase. , 2003, Biochemical and biophysical research communications.

[35]  S. T. Kim,et al.  ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. , 2001, Genes & development.

[36]  J. Manfredi.  The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. , 2010, Genes & development.

[37]  Ying Li,et al.  Stimulation of human DNA polymerase epsilon by MDM2. , 2003, Nucleic acids research.

[38]  D. Givol,et al.  Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells , 2010, Oncogene.

[39]  R. Hay,et al.  Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation , 2000, Molecular and Cellular Biology.

[40]  T. Jacks,et al.  Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. , 2011, Molecular cell.

[41]  G. Wahl,et al.  MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.

[42]  Y. Shiloh,et al.  ATM-Mediated Phosphorylations Inhibit Mdmx/Mdm2 Stabilization by HAUSP in Favor of p53 Activation , 2005, Cell cycle.

[43]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[44]  X. Jacq,et al.  Ribosomal protein S7 is both a regulator and a substrate of MDM2. , 2009, Molecular cell.

[45]  Xinbin Chen,et al.  MDM2 Is a Negative Regulator of p21WAF1/CIP1, Independent of p53* , 2004, Journal of Biological Chemistry.

[46]  T. Lushnikova,et al.  Mdm2 Promotes Genetic Instability and Transformation Independent of p53 , 2008, Molecular and Cellular Biology.

[47]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[48]  D. George,et al.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.

[49]  M. Yaniv,et al.  Wild-type p53 can down-modulate the activity of various promoters. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  C. Prives,et al.  The C-terminus of p53 binds the N-terminal domain of MDM2 , 2010, Nature Structural &Molecular Biology.

[51]  M. Kitagawa,et al.  Enhanced Mdm2 activity inhibits pRB function via ubiquitin‐dependent degradation , 2005, The EMBO journal.

[52]  P. Rothberg,et al.  Oncogenes and cancer. , 1983, Cancer investigation.

[53]  G. D’Orazi,et al.  Updates on HIPK2: a resourceful oncosuppressor for clearing cancer , 2012, Journal of experimental & clinical cancer research : CR.

[54]  J. Roth,et al.  Multiple Lysine Mutations in the C-Terminal Domain of p53 Interfere with MDM2-Dependent Protein Degradation and Ubiquitination , 2000, Molecular and Cellular Biology.

[55]  Ruiwen Zhang,et al.  Natural product MDM2 inhibitors: anticancer activity and mechanisms of action. , 2012, Current medicinal chemistry.

[56]  T. Lindahl.  Genetic instability in cancer , 1996 .

[57]  L. Vassilev.  Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics , 2004, Cell cycle.

[58]  G. Dubin,et al.  Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73 , 2010, Cell cycle.

[59]  N. L. La Thangue,et al.  Mdm2 targets the p53 transcription cofactor JMY for degradation , 2007, EMBO reports.

[60]  Min Wu,et al.  The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. , 2002, Cancer letters.

[61]  Hongtae Kim,et al.  Merlin Neutralizes the Inhibitory Effect of Mdm2 on p53* , 2004, Journal of Biological Chemistry.

[62]  M. Tutone,et al.  Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. , 2010, Current medicinal chemistry.

[63]  Yaping Li,et al.  Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles. , 2013, Biomaterials.

[64]  Xin Lu,et al.  RB regulates the stability and the apoptotic function of p53 via MDM2. , 1999, Molecular cell.

[65]  M. Dai,et al.  Inhibition of MDM2-mediated p53 Ubiquitination and Degradation by Ribosomal Protein L5* , 2004, Journal of Biological Chemistry.

[66]  Hui Wang,et al.  Identification of ribosomal protein S25 (RPS25)–MDM2–p53 regulatory feedback loop , 2013, Oncogene.

[67]  Hui Wang,et al.  Oncogenes as Novel Targets for Cancer Therapy (Part III) , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[68]  S. Grossman,et al.  Yin Yang 1 Is a Negative Regulator of p53 , 2004, Cell.

[69]  H. Anders,et al.  p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. , 2012, Neoplasia.

[70]  H. Hermeking,et al.  The p53/microRNA network in cancer: experimental and bioinformatics approaches. , 2013, Advances in experimental medicine and biology.

[71]  M. Koeppel,et al.  Specific inhibition of Mdm2-mediated neddylation by Tip60 , 2008, Cell cycle.

[72]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[73]  W. Gu,et al.  The multiple levels of regulation by p53 ubiquitination , 2010, Cell Death and Differentiation.

[74]  L. Vassilev,et al.  Targeting the p53–MDM2 interaction to treat cancer , 2004, British Journal of Cancer.

[75]  A. Levine,et al.  Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. , 1993, Oncogene.

[76]  C. Korgaonkar,et al.  Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function , 2005, Molecular and Cellular Biology.

[77]  M. Dai,et al.  Ribosomal Protein L23 Activates p53 by Inhibiting MDM2 Function in Response to Ribosomal Perturbation but Not to Translation Inhibition , 2004, Molecular and Cellular Biology.

[78]  H. He,et al.  Ribosomal protein S27L is a direct p53 target that regulates apoptosis , 2007, Oncogene.

[79]  R. Honda,et al.  Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.

[80]  H. Kawai,et al.  The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo , 2011, Proceedings of the National Academy of Sciences.

[81]  Chandra S Verma,et al.  On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study , 2013, Cell cycle.

[82]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[83]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[84]  B. Wasylyk,et al.  MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. , 1995, Oncogene.

[85]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[86]  Guoqiang Dong,et al.  Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. , 2012, Journal of medicinal chemistry.

[87]  Guillermina Lozano,et al.  Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy , 2012, Clinical Cancer Research.

[88]  F. Frasca,et al.  TAp73α Increases p53 Tumor Suppressor Activity in Thyroid Cancer Cells via the Inhibition of Mdm2-Mediated Degradation , 2008, Molecular Cancer Research.

[89]  L. Johnson,et al.  Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1 , 2010, Apoptosis.

[90]  Patrick E Carroll,et al.  Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression , 1999, Oncogene.

[91]  S. Majid,et al.  The Role of miR-18b in MDM2-p53 Pathway Signaling and Melanoma Progression , 2013, Journal of the National Cancer Institute.

[92]  Jun Fang,et al.  RNF2/Ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development , 2013, Proceedings of the National Academy of Sciences.

[93]  Jean-Christophe Marine,et al.  Mdmx as an essential regulator of p53 activity. , 2005, Biochemical and biophysical research communications.

[94]  T. Allio,et al.  Ribosomal Protein L11 Negatively Regulates Oncoprotein MDM2 and Mediates a p53-Dependent Ribosomal-Stress Checkpoint Pathway , 2003, Molecular and Cellular Biology.

[95]  Ying Li,et al.  Stimulation of human DNA polymerase ϵ by MDM2 , 2003 .

[96]  D. Cervi,et al.  Direct transcriptional regulation of MDM2 by Fli-1 , 2005, Oncogene.

[97]  Tomoko Masuda,et al.  The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. , 2005, Cancer cell.

[98]  B. K. Park,et al.  MDM2 regulates dihydrofolate reductase activity through monoubiquitination. , 2008, Cancer research.

[99]  Jorge Zerón-Medina,et al.  Single-nucleotide polymorphisms in the p53 signaling pathway. , 2010, Cold Spring Harbor perspectives in biology.

[100]  M. Jiang,et al.  Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53 , 2010, Molecular Biology Reports.

[101]  N. L. La Thangue,et al.  Actin nucleation by a transcription co-factor that links cytoskeletal events with the p53 response , 2010, Cell cycle.

[102]  Ruiwen Zhang,et al.  Recent advances in validating MDM2 as a cancer target. , 2009, Anti-cancer agents in medicinal chemistry.

[103]  J. Dennis,et al.  A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization , 2008, Apoptosis.

[104]  H. Saito,et al.  Overexpression of the MDM2 oncogene in leukemia and lymphoma. , 1996, Leukemia & lymphoma.

[105]  Pankaj Oberoi,et al.  Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. , 2005, Cancer cell.

[106]  Yanping Zhang,et al.  Signaling to p53: ribosomal proteins find their way. , 2009, Cancer cell.

[107]  A. Levine,et al.  Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. , 1994, Cancer research.

[108]  J. Qin,et al.  Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization , 2002, Nature.

[109]  M. Roussel,et al.  Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex , 2000, Molecular and Cellular Biology.

[110]  E. Appella,et al.  PML enhances the regulation of p53 by CK1 in response to DNA damage , 2008, Oncogene.

[111]  Shengyun Fang,et al.  Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.

[112]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[113]  Ruiwen Zhang,et al.  MDM2 Promotes Proteasomal Degradation of p21Waf1 via a Conformation Change* , 2010, The Journal of Biological Chemistry.

[114]  Hui Zhao,et al.  MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells. , 2012, Acta biochimica et biophysica Sinica.

[115]  Mong-Hong Lee,et al.  14-3-3 sigma positively regulates p53 and suppresses tumor growth. , 2003, Molecular and cellular biology.

[116]  Hua Lu,et al.  Nucleostemin: Another nucleolar "Twister" of the p53-MDM2 loop. , 2010, Cell cycle.

[117]  Shubhra Ghosh Dastidar,et al.  Rational design and biophysical characterization of thioredoxin-based aptamers: insights into peptide grafting. , 2010, Journal of molecular biology.

[118]  S. Guerrera,et al.  MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon. , 2000, Nucleic acids research.

[119]  Thokhir Basha Shaik,et al.  p53–Mdm2 inhibitors: patent review (2009 – 2010) , 2012, Expert opinion on therapeutic patents.

[120]  M. Oren,et al.  Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. , 1994, Genes & development.

[121]  D. Haines,et al.  A Novel Cellular Protein (MTBP) Binds to MDM2 and Induces a G1 Arrest That Is Suppressed by MDM2* , 2000, The Journal of Biological Chemistry.

[122]  B. Peng,et al.  A novel oncoprotein Pirh2: rising from the shadow of MDM2 , 2011, Cancer science.

[123]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[124]  C. M. Eischen,et al.  Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair* , 2005, Journal of Biological Chemistry.

[125]  Ruiwen Zhang,et al.  Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation , 2008, The EMBO journal.

[126]  Hui Wang,et al.  MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. , 2005, Current cancer drug targets.

[127]  H. Tsukada,et al.  Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy. , 2013, Biological & pharmaceutical bulletin.

[128]  A. El‐Naggar,et al.  An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2 , 2001, Oncogene.

[129]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[130]  F. Mancini,et al.  MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. , 2007, Molecular cell.

[131]  R. Copeland,et al.  Human mdm2 Mediates Multiple Mono-ubiquitination of p53 by a Mechanism Requiring Enzyme Isomerization* , 2001, The Journal of Biological Chemistry.

[132]  Hui Wang,et al.  Transcription Factor NFAT1 Activates the mdm2 Oncogene Independent of p53* , 2012, The Journal of Biological Chemistry.

[133]  B. Vogelstein,et al.  HAUSP is Required for p53 Destabilization , 2004, Cell cycle.

[134]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[135]  T. Hofmann,et al.  Apoptosis and autophagy: Regulation of apoptosis by DNA damage signalling – roles of p53, p73 and HIPK2 , 2009, The FEBS journal.

[136]  W. Wang,et al.  Ribosomal protein S7 as a novel modulator of p53–MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function , 2007, Oncogene.

[137]  T. Holak,et al.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain , 2008, Cell cycle.

[138]  Q. Sun,et al.  Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop , 2013, Oncogene.

[139]  D. Durden,et al.  Regulation of XIAP translation and induction by MDM2 following irradiation. , 2009, Cancer cell.

[140]  M. Boyd,et al.  Regulation of p53 and MDM2 Activity by MTBP , 2005, Molecular and Cellular Biology.

[141]  R. Breitling,et al.  Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells , 2011, Cell Death and Disease.

[142]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[143]  T. Dörk,et al.  Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. , 2007, Cancer research.

[144]  P. Chène.  Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[145]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[146]  L. Ellis,et al.  Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. , 2000, Cancer research.

[147]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[148]  A. Levine,et al.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.

[149]  H. Hsu,et al.  MDM2 Overexpression Deregulates the Transcriptional Control of RB/E2F Leading to DNA Methyltransferase 3A Overexpression in Lung Cancer , 2012, Clinical Cancer Research.

[150]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[151]  Kristian Helin,et al.  Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity , 2004, Molecular and Cellular Biology.

[152]  Wei Wu,et al.  MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis , 2011, BMC Cancer.

[153]  Yi Sun,et al.  Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis s a target, a substrate, and a regulator , 2010, Oncogene.

[154]  René Bernards,et al.  An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors , 2006, Nature chemical biology.

[155]  Alberto Inga,et al.  The expanding universe of p53 targets , 2009, Nature Reviews Cancer.

[156]  R. Vatsyayan,et al.  Nutlin‐3 enhances sorafenib efficacy in renal cell carcinoma , 2013, Molecular carcinogenesis.

[157]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[158]  L. Saucedo,et al.  p76MDM2 Inhibits the Ability of p90MDM2to Destabilize p53* , 2000, The Journal of Biological Chemistry.

[159]  F. Zindy,et al.  p53-Dependent and -independent functions of the Arf tumor suppressor. , 2005, Cold Spring Harbor symposia on quantitative biology.

[160]  H. Schünemann,et al.  Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties , 2008, Journal of Molecular Medicine.

[161]  D. Terrian,et al.  p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3 , 2012, Cell cycle.

[162]  Y. Yoo,et al.  Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation , 2013, Anti-cancer drugs.

[163]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[164]  C. Sherr,et al.  Ubiquitination of, and sumoylation by, the Arf tumor suppressor. , 2006, The Israel Medical Association journal : IMAJ.